The bladder cancer therapeutics market was valued at $670m in 2018 across the seven major markets (7MM*) and is expected to grow exponentially at a compound annual growth rate (CAGR) of 23.6% – accruing slightly less than $5.6bn in 2028, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Bladder Cancer Opportunity Analysis and Forecasts to 2028’, highlights that this market growth is driven by the introduction of novel agents and label expansions of key products such as immune checkpoint inhibitors across all treatment settings for both muscle invasive and non-muscle invasive bladder cancer.
Ufuk Ezer, MSc, Oncology and Hematology Analyst at GlobalData, comments: “The treatment paradigm for bladder cancer is expected to transform rapidly due to recently approved novel targeted therapies such as Padcev and Balversa. While immune checkpoint inhibitors are expected to have increased use in treating muscle invasive, locally advanced or metastatic bladder cancer, anticipated approvals of the gene therapy instiladrin, targeted therapy vicinium and novel immunotherapies such as CG0070 and N-803 are expected to benefit patients with superficial or non-muscle invasive bladder cancer. Nonetheless, for these patients, Bacillus Calmette-Guerin (BCG) is expected to remain as an important treatment option despite the introduction of new therapies.”
Key opinion leaders (KOLs) interviewed by GlobalData believe that therapies such as Padcev and its combination with Keytruda, sacituzumab govitecan, and bempegaldesleukin in combination with Opdivo, carry tremendous potential to benefit muscle invasive, locally advanced and metastatic bladder cancer patients.
Ezer continues: “Following its approval in late 2019, Padcev surprised the market with its high uptake in the US, and will continue its penetration in all major markets across the advanced bladder cancer patient segment, owing to high usage in ‘all-comers’. Furthermore, with the approval of novel immune checkpoint inhibitor targeted combination therapies, and biomarker-driven treatment approaches, patients will benefit from more diversified and personalized treatment options starting from neoadjuvant and adjuvant treatment lines.
“By 2028, targeted therapies are forecast to represent roughly 46% of the bladder cancer market across the 7MM, closely followed by immunotherapies. The leading therapies in terms of total annual sales in 2028 will be Padcev and Keytruda, with forecast annual sales of $2.1bn and $1.1bn respectively.”
*7MM = The US, France, Germany, Italy, Spain, the UK and Japan